I. AMENDMENT

Amendment to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-25 (Canceled)

Claim 26 (Currently Amended): An antibody specifically binding at least one epitope of a heparanase protein, said heparanase protein: a) having an amino acid sequence as set forth in SEQ ID NO:2; b) having an amino acid sequence as set forth in SEQ ID NO:2, provided that said amino acid sequence has a phenylalanine residue instead of a tyrosine residue at position 246; or c) having endoglycosidase activity and being a fragment ~~being an active form~~ of a) or b)), wherein said antibody can recognize said protein .

Claim 27 (Previously Presented): The antibody of claim 26, wherein said heparanase protein is recombinant.

Claim 28 (Previously Presented): The antibody of claim 26, wherein elicitation of the antibody is through in vivo or in vitro techniques, said antibody having been prepared by a process comprising the steps of:

(a) exposing cells capable of producing antibodies to said at least one epitope of said heparanase protein and thereby generating antibody producing cells;

(b) fusing said antibody producing cells with myeloma cells and thereby generating a plurality of hybridoma cells each producing monoclonal antibodies; and

(c) screening said plurality of monoclonal antibodies to identify a monoclonal antibody which specifically binds heparanase.

Claim 29 (Previously Presented): The antibody of claim 26, wherein the antibody is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.

Claim 30 (Previously Presented): The antibody of claim 29, wherein said polyclonal antibody is selected from the group consisting of a crude polyclonal antibody and an affinity purified polyclonal antibody.

Claim 31 (Currently Amended): The antibody of claim 26, wherein said ~~active form of said~~ heparanase protein has endoglycosidase hydrolyzing activity.

Claim 32 (Currently Amended): An antibody elicited by at least one epitope of a heparanase protein, said heparanase protein: a) having an amino acid sequence as set forth in SEQ ID NO:2; b) having an amino acid sequence as set forth in SEQ ID NO:2, provided that said amino acid sequence has a phenylalanine residue instead of a tyrosine residue at position 246; or c) having endoglycosidase activity and being a fragment ~~being an active form~~ of a) or b), wherein said antibody can recognize said protein.

Claim 33 (Previously Presented): The antibody of claim 32, wherein said heparanase protein is recombinant.

Claim 34 (Previously Presented): The antibody of claim 32, wherein elicitation of the antibody is through in vivo or in vitro techniques, said antibody having been prepared by a process comprising the steps of:

(a) exposing cells capable of producing antibodies to said at least one epitope of said heparanase protein and thereby generating antibody producing cells;

(b) fusing said antibody producing cells with myeloma cells and thereby generating a plurality of hybridoma cells each producing monoclonal antibodies; and

(c) screening said plurality of monoclonal antibodies to identify a monoclonal antibody which specifically binds heparanase.

Claim 35 (Previously Presented): The antibody of claim 32, wherein the antibody is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.

Claim 36 (Previously Presented): The antibody of claim 35, wherein said polyclonal antibody is selected from the group consisting of a crude polyclonal antibody and an affinity purified polyclonal antibody.

Claim 37 (Currently Amended): The antibody of claim 32, wherein said ~~active form of said~~ heparanase protein has endoglycosidase hydrolyzing activity.